Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: A randomized controlled study

American Journal of Nephrology

Volumn 35, Issue 5, 2012, Pages 416-423

  Takenaka, Tsuneo ^a   Seto, Takeru ^a   Okayama, Mika ^a   Kojima, Eriko ^a   Nodaira, Yuka ^a   Sueyoshi, Keita ^a   Kikuta, Tomohiro ^a   Watanabe, Yusuke ^a   Inoue, Tsutomu ^a   Takane, Hiroshi ^a   Ohno, Yoichi ^a   Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Cardiovascular disease; Central blood pressure; Glomerular capillary pressure; Sympathetic nervous system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CREATININE; DIURETIC AGENT; LOSARTAN; MANIDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; OLMESARTAN; TELMISARTAN; UNCLASSIFIED DRUG; VALNIDIPINE; VALSARTAN;

AGED; ANKLE EDEMA; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART PALPITATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; PULSE RATE; RANDOMIZED CONTROLLED TRIAL;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TIME;

EID: 84859874167     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000338132     Document Type: Article

References (30)

1. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeld-sen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro-flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BP-LA): a multicentre randomised controlled tria l. Lancet 2005; 366: 895-906. (Pubitemid 41265663)
2. Williams B, Lacy PS, Thom SM, Cruick-shank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
3. Williams B, Lacy PS, CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators: Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol 2009; 54:705-713.
4. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial Investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
5. Guidelines for the management of chronic kidney diseases; in: Hypertension. Tokyo-Iga ku, Japa nese Socie t y of Hy per tension and Japanese Society of Nephrology 2008; pp 5-29. http://www.jpnsh.org/data/CKD-kouketsuatsu. pdf.
6. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72:1543-1549. (Pubitemid 350199443)
7. Zhou X, Ono H, Ono Y, Frohlich ED: N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe neph-rosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hy-pertens 2002; 20:993-1000. (Pubitemid 34913681)
8. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T: Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100:342-353.
9. Takenaka T, Takane H, Okada H, Ohno Y, Suzuki H: Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney diseases. NDT Plus 2009; 2: 192-193.
10. Sada T, Saito H: Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker. Folia Pharmacol Jpn 2003; 122: 539-547. (Pubitemid 38019946)
11. Furukawa T, Nukada T, Namiki Y, Miyashita Y, Hatsuno K, Ueno Y, Yamakawa T, Isshiki T: Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (C a(v)3.1 (a lpha(1G)), Ca(v)3. 2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xeno-pus oocytes. Eur J Pharmacol 2009; 613:100-107.
12. Miyashita H, Aizawa A, Hashimoto J, Hirook a Y, Imai Y, Kawano Y, Kohara K, Sunagawa K, Suzuki H, Tabara Y, Takazawa K, Takenaka T, Yasuda H, Shimada K: Cross-sectional characterization of all classes of antihyper-tensives in terms of central blood pressure in Japanese hypertensive patients. Am J Hyper-tens 2010; 23: 260-268.
13. Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K: Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hy pertension 2009; 54: 716-723.
14. Kobayashi K, Ohno Y, Takenaka T, Ikeda N, Okada H, Kanno Y, Suzuki H: Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes. Clin Exp Hypertens 2011; 33:100-105.
15. Takenaka T, Mimura T, Kanno Y, Suzuki H: Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. Am J Nephrol 2005; 25:417-424. (Pubitemid 41433884)
16. Takenaka T, Sato T, Hoshi H, Kato N, Sueyoshi K, Tsuda M, Watanabe Y, Takane H, Ohno Y, Suzuki H: Height constitutes an important predictor of mortality in end-stage renal disease. Cardiol Res Pract 2010; 2011: 242353.
17. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A: Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007; 30:219-228. (Pubitemid 46605446)
18. Kanno Y, Takenaka T, Nakamura T, Suzuki H: Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angioten-sin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2006; 1:730-737.
19. Kumagai H, Onami T, Iigaya K, Takimoto C, Hayashi K, Saruta T: Mechanisms for reduced heart rate by azelnidipine: analysis on central and peripheral sympathetic nerves. Prog Med 2004; 24: 2659-2664.
20. Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Su nagawa K: A zel nid ipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2008; 52:555-560.
21. Hermsmeyer K: Role of T cha n nels i n card io-vascular function. Cardiology 1998; 89(suppl 1):2-9.
22. Lin MM, Cheng HM, Sung SH, Liao CF, Chen YH, Huang PH, Chen CH: Estimation of central aortic systolic pressure from the second systolic peak of the peripheral upper limb pulse depends on central aortic pressure waveform morphology. J Hypertens 2012; 30: 581-586.
23. Asmar RG, London GM, O'Rourke ME, Sa-far ME, REASON Project Coordinators and Investigators: Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indap-amide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38:922-926. (Pubitemid 34258694)
24. Takenaka T, Suzuki H, Okada H, Inoue T, Kanno Y, Ozawa Y, Hayashi K, Saruta T: Transient receptor potential channels in rat renal microcirculation: actions of angioten-sin II. Kidney Int 2002; 62: 558-565. (Pubitemid 34779768)
25. O'Rourke MF, Safar ME: Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hy pertension 2005; 46: 200-204. (Pubitemid 40946514)
26. Covic A, Haydar AA, Bhamra-Ariza P, Gus-beth-Tatomir P, Goldsmith DJ: Aortic pulse wave velocity and arterial wave reflections predict the extent and severity of coronary artery disease in chronic kidney disease patients. J Nephrol 2005; 18: 388-396. (Pubitemid 41700101)
27. Nishiura R, Kita T, Yamada K, Komatsu H, Hara S, Sato Y, Fujimoto S: Radial aug mentation index is related to cardiovascula r risk in hemodialysis patients. Ther Apher Dial 2008; 12:157-163. (Pubitemid 351490251)
28. Mimura T, Takenaka T, Kanno Y, Moriwaki K, Okada H, Suzuki H: Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hypertens 2008; 22:38-47. (Pubitemid 350269254)
29. Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, Fujisawa Y, Lu XM, Fu H, Du J, Ohm-ori K, Hosomi N, Kimura S, Kiyomoto H, Nishiyama A: Inhibitory effects of a dihy-dropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J Hy-pertens 2009; 27:1855-1862.
30. Takazawa K, Tanaka N, Takeda K, Kurosu F, Ibukiyama C: Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. Hy pertension 1995; 26: 520-523.